Stock News
Innovative, Articulate, and Easy to Follow: A Professional and Blog-Friendly Rewrite of Accesswire Article 924706
Klondike Gold Corp. Closes Non-Brokered Private Placement Financing Overview Klondike Gold Corp. recently announced the closure of its non-brokered private placement financing, raising $409,000. The company issued 2,785,000 flow-through units at a price of $0.10 per unit, with each unit consisting of one flow-through share and one share purchase warrant. Implications This private placement financing…
Oops, We Did It Again: 111 Inc. Gets a Note from NASDAQ!
Shanghai Healthcare Company Faces NASDAQ Challenge What Happened So, imagine this: you’re a healthcare company based in Shanghai, trying to make waves in the industry and revolutionize how healthcare is delivered in China. You’re feeling pretty good about yourself, until one day, you receive a notification letter from Nasdaq. It’s like getting a report card…
CARVYKTI: The Revolutionary Cell Therapy Paving the Way for Longer Survival in Multiple Myeloma Patients as Early as Second Line Treatment
Groundbreaking Results from Legend Biotech Corporation’s Phase 3 CARTITUDE-4 Study Introduction SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN), a leading global player in cell therapy, made a significant announcement today. The three-year follow-up data from the Phase 3 CARTITUDE-4 study has shown remarkable results in patients with relapsed or…
Say Goodbye to Multiple Myeloma: Carvykti – The Revolutionary Cell Therapy that Prolongs Survival!
Say Goodbye to Multiple Myeloma: Carvykti – The Revolutionary Cell Therapy that Prolongs Survival! Description: 45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ —…
Unlocking the Magic: A Playful and Relatable Look at the Power of Accessing Your Dreams
Ensysce Biosciences, Inc. Faces Delisting from Nasdaq What Happened? Ensysce Biosciences, Inc. (NASDAQ:ENSC) recently received notice from Nasdaq that the company has not met compliance requirements due to its stock price remaining below $1.00 per share for the initial 180-day period. What Does This Mean for Ensysce Biosciences, Inc.? Unfortunately, Ensysce Biosciences, Inc. is now…
Innovative Equity Incentive Award Granted to New Employee at PacBio
PacBio Grants Stock Options and RSUs to New Employee Introduction MENLO PARK, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — PacBio, a leading provider of high-quality, highly accurate sequencing platforms, recently announced the grant of non-qualified stock options and restricted stock units to a newly hired employee. This move was made under the Pacific Biosciences 2020…
Attention Investors: Bronstein, Gewirtz & Grossman LLC Launches Investigation into Joint Stock Company Kaspi.kz – Take Action Now!
Welcome to our Blog Post! Investigating Potential Claims Against Kaspi.kz Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC is currently investigating potential claims on behalf of purchasers of Joint Stock Company Kaspi.kz (“Kaspi” or “the Company”) (NASDAQ: KSPI). If you have invested in Kaspi securities, we encourage you to obtain additional information and assist with…
Breaking News: Atos SE Receives Overwhelming Support from Shareholders and Creditors! Find Out Why This Accelerated Safeguard Plan is a Game-Changer
Exciting News from Atos SE! Strong Support for Draft Accelerated Safeguard Plan Paris, France – September 27, 2024 – Atos SE (“Atos” or the “Company”) is thrilled to announce that its shareholders and financial creditors have shown overwhelming support for the proposed draft accelerated safeguard plan. All three classes of affected parties have voted in…